G1 Therapeutics stock movements

G1 Therapeutics (GTHX), a clinical-stage company, has risen 242.59% YTD (year-to-date), mainly due to its three important oncology research programs achieving major milestones. It was led by its most advanced clinical program for investigational first-in-class, short-acting, intravenously-administered cyclin-dependent kinase 4/6 (or CDK 4/6) inhibitor trilaciclib in the first half of 2018.

The consensus recommendation for G1 Therapeutics over the next 12 months is a “buy.” Of the six analysts covering the company in September, two have recommended a “strong buy,” and four have recommended a “buy.”

Wall Street analysts have projected a 12-month consensus target price for G1 Therapeutics of $67, which would be a decline of 1.43% over its closing price on September 13.

G1 Therapeutics Posted 242.59% Returns Year-to-DateThe above chart highlights the key milestone events that could impact G1 Therapeutics stock in the future.

Growth drivers

G1 Therapeutics is targeting the myelopreservation market, worth more than $7 billion, with trilaciclib, which is currently being evaluated in multiple Phase 2 trials. The drug is being tested as a backbone therapy in combination regimens in first-line, second-line, and third-line small cell lung cancer, as well as in metastatic triple-negative breast cancers. All these indications are hard to treat, and the company thus expects to benefit from significant unmet demand in those areas.

It’s also targeting the oral CDK4/6 market, worth more than $20 billion, with investigational CDK4/6 inhibitor lerociclib. G1 It’s also targeting the selective estrogen receptor degrader (or SERD) market in the ER+ (estrogen-receptor-positive) breast cancer segment, which is worth more than $1 billion.

As of June 30, G1 Therapeutics had $188.2 million in cash on its balance sheet.

In the next part, we’ll look at the growth trends for Sarepta Therapeutics.

Latest articles

If there’s one thing critics and fans agree on when it comes to Bitcoin, it’s the volatility factor. The moves are big, and timid investors need not apply.

In this year’s annual shareholder letter, Berkshire Hathaway (BRK.B) CEO Warren Buffett discussed the possibility of an “elephant-sized acquisition."

The esports industry is thriving. Let's take a look at the expected growth in esports viewership and the total available market in the space.

Today, Jeff Bezos detailed Amazon's plans for sweeping sustainability initiatives. Bezos's announcement came a day before the Global Climate Strike.

Integrated oil companies ExxonMobil and Chevron have strong upstream portfolios, which play a vital role in determining their profitabilities.

Adobe (ADBE) released its fiscal 2019 third-quarter earnings results on September 17. Overall, its third-quarter results exceeded expectations.